Frequent expression of napsin a in clear cell carcinoma of the endometrium

Potential diagnostic utility

Oluwole Fadare, Mohamed M. Desouki, Katja Gwin, Krisztina Z. Hanley, Elke A. Jarboe, Sharon X. Liang, Charles M. Quick, Wenxin - Zheng, Vinita Parkash, Jonathan L. Hecht

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The histotyping of high-grade endometrial carcinomas with clear cells may be subject to significant interobserver variability, which suggests that a biomarker that can distinguish endometrial clear cell carcinoma (CCC) from its mimics would be of diagnostic utility. This study assessed the usefulness of napsin A immunohistochemistry in the diagnosis of CCC, on the basis of an analysis of 77 cases diagnosed as such at 9 institutions. After being independently reviewed by a subset of 3 pathologists, cases for which there was diagnostic consensus among all 3 reviewers in agreement with the primary contributor (n=60) were used to establish a "consensus group" that served as a gold standard relative to which napsin A performance was assessed. Duplicate, 1.0-mm-core tissue microarrays were constructed from the 54 cases in the consensus group for which requisite materials were available, as well as from 49 endometrial endometrioid carcinomas (all grades) and 17 endometrial serous carcinomas. Napsin A immunohistochemical analysis was performed on the microarrays and on the 17 cases for which there was no diagnostic consensus, with scoring based on the proportion of immunoreactive cells (0, 1+, 2+, and 3+ indicative of 0, 1% to 25%, 26% to 49%, and ≥50% immunoreactive cells, respectively). The distribution of scores for the 49 CCC cases with evaluable cores was as follows: 0, n=6; 1+, n=6; 2+, n=8; 3+, n=29. Among the evaluable cases, the frequency of ≥1+ napsin A immunoreactivity was significantly higher in CCCs (43/49, 88%) than in endometrial serous carcinomas (1/13, 7.7%; P<0.0001) and endometrial endometrioid carcinomas (0/49, 0%; P<0.0001). The sensitivity, specificity, negative predictive value, and positive predictive value of ≥1+ napsin A expression in predicting the consensus clear cell histotype were 0.88 (95% confidence interval [CI], 0.75-0.95), 0.98 (95% CI, 0.9-1), 0.91 (95% CI, 0.86-0.96), and 0.98 (95% CI, 0.86-1), respectively. Napsin A expression was not associated with survival or clinicopathologic factors. In the group of cases without diagnostic consensus for CCC, 50% showed ≥1+ napsin A expression; all napsin A-negative cases had previously been classified as non-CCC by ≥2 reviewers, whereas only 37.5% of the napsin A-positive cases had been classified as CCC by 2 of the 3 reviewers. In conclusion, napsin A is a sensitive and specific biomarker of the clear cell histotype in endometrial carcinomas and accordingly may have diagnostic utility in their histotyping.

Original languageEnglish (US)
Pages (from-to)189-196
Number of pages8
JournalAmerican Journal of Surgical Pathology
Volume38
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Endometrial Neoplasms
Carcinoma
Confidence Intervals
Endometrioid Carcinoma
Biomarkers
Observer Variation
Immunohistochemistry
Sensitivity and Specificity

Keywords

  • endometrial clear cell carcinoma
  • immunohistochemistry
  • napsin A

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

Fadare, O., Desouki, M. M., Gwin, K., Hanley, K. Z., Jarboe, E. A., Liang, S. X., ... Hecht, J. L. (2014). Frequent expression of napsin a in clear cell carcinoma of the endometrium: Potential diagnostic utility. American Journal of Surgical Pathology, 38(2), 189-196. https://doi.org/10.1097/PAS.0000000000000085

Frequent expression of napsin a in clear cell carcinoma of the endometrium : Potential diagnostic utility. / Fadare, Oluwole; Desouki, Mohamed M.; Gwin, Katja; Hanley, Krisztina Z.; Jarboe, Elke A.; Liang, Sharon X.; Quick, Charles M.; Zheng, Wenxin -; Parkash, Vinita; Hecht, Jonathan L.

In: American Journal of Surgical Pathology, Vol. 38, No. 2, 02.2014, p. 189-196.

Research output: Contribution to journalArticle

Fadare, O, Desouki, MM, Gwin, K, Hanley, KZ, Jarboe, EA, Liang, SX, Quick, CM, Zheng, W, Parkash, V & Hecht, JL 2014, 'Frequent expression of napsin a in clear cell carcinoma of the endometrium: Potential diagnostic utility', American Journal of Surgical Pathology, vol. 38, no. 2, pp. 189-196. https://doi.org/10.1097/PAS.0000000000000085
Fadare, Oluwole ; Desouki, Mohamed M. ; Gwin, Katja ; Hanley, Krisztina Z. ; Jarboe, Elke A. ; Liang, Sharon X. ; Quick, Charles M. ; Zheng, Wenxin - ; Parkash, Vinita ; Hecht, Jonathan L. / Frequent expression of napsin a in clear cell carcinoma of the endometrium : Potential diagnostic utility. In: American Journal of Surgical Pathology. 2014 ; Vol. 38, No. 2. pp. 189-196.
@article{b867c2d754e94b04a2be1640e4e8f59b,
title = "Frequent expression of napsin a in clear cell carcinoma of the endometrium: Potential diagnostic utility",
abstract = "The histotyping of high-grade endometrial carcinomas with clear cells may be subject to significant interobserver variability, which suggests that a biomarker that can distinguish endometrial clear cell carcinoma (CCC) from its mimics would be of diagnostic utility. This study assessed the usefulness of napsin A immunohistochemistry in the diagnosis of CCC, on the basis of an analysis of 77 cases diagnosed as such at 9 institutions. After being independently reviewed by a subset of 3 pathologists, cases for which there was diagnostic consensus among all 3 reviewers in agreement with the primary contributor (n=60) were used to establish a {"}consensus group{"} that served as a gold standard relative to which napsin A performance was assessed. Duplicate, 1.0-mm-core tissue microarrays were constructed from the 54 cases in the consensus group for which requisite materials were available, as well as from 49 endometrial endometrioid carcinomas (all grades) and 17 endometrial serous carcinomas. Napsin A immunohistochemical analysis was performed on the microarrays and on the 17 cases for which there was no diagnostic consensus, with scoring based on the proportion of immunoreactive cells (0, 1+, 2+, and 3+ indicative of 0, 1{\%} to 25{\%}, 26{\%} to 49{\%}, and ≥50{\%} immunoreactive cells, respectively). The distribution of scores for the 49 CCC cases with evaluable cores was as follows: 0, n=6; 1+, n=6; 2+, n=8; 3+, n=29. Among the evaluable cases, the frequency of ≥1+ napsin A immunoreactivity was significantly higher in CCCs (43/49, 88{\%}) than in endometrial serous carcinomas (1/13, 7.7{\%}; P<0.0001) and endometrial endometrioid carcinomas (0/49, 0{\%}; P<0.0001). The sensitivity, specificity, negative predictive value, and positive predictive value of ≥1+ napsin A expression in predicting the consensus clear cell histotype were 0.88 (95{\%} confidence interval [CI], 0.75-0.95), 0.98 (95{\%} CI, 0.9-1), 0.91 (95{\%} CI, 0.86-0.96), and 0.98 (95{\%} CI, 0.86-1), respectively. Napsin A expression was not associated with survival or clinicopathologic factors. In the group of cases without diagnostic consensus for CCC, 50{\%} showed ≥1+ napsin A expression; all napsin A-negative cases had previously been classified as non-CCC by ≥2 reviewers, whereas only 37.5{\%} of the napsin A-positive cases had been classified as CCC by 2 of the 3 reviewers. In conclusion, napsin A is a sensitive and specific biomarker of the clear cell histotype in endometrial carcinomas and accordingly may have diagnostic utility in their histotyping.",
keywords = "endometrial clear cell carcinoma, immunohistochemistry, napsin A",
author = "Oluwole Fadare and Desouki, {Mohamed M.} and Katja Gwin and Hanley, {Krisztina Z.} and Jarboe, {Elke A.} and Liang, {Sharon X.} and Quick, {Charles M.} and Zheng, {Wenxin -} and Vinita Parkash and Hecht, {Jonathan L.}",
year = "2014",
month = "2",
doi = "10.1097/PAS.0000000000000085",
language = "English (US)",
volume = "38",
pages = "189--196",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Frequent expression of napsin a in clear cell carcinoma of the endometrium

T2 - Potential diagnostic utility

AU - Fadare, Oluwole

AU - Desouki, Mohamed M.

AU - Gwin, Katja

AU - Hanley, Krisztina Z.

AU - Jarboe, Elke A.

AU - Liang, Sharon X.

AU - Quick, Charles M.

AU - Zheng, Wenxin -

AU - Parkash, Vinita

AU - Hecht, Jonathan L.

PY - 2014/2

Y1 - 2014/2

N2 - The histotyping of high-grade endometrial carcinomas with clear cells may be subject to significant interobserver variability, which suggests that a biomarker that can distinguish endometrial clear cell carcinoma (CCC) from its mimics would be of diagnostic utility. This study assessed the usefulness of napsin A immunohistochemistry in the diagnosis of CCC, on the basis of an analysis of 77 cases diagnosed as such at 9 institutions. After being independently reviewed by a subset of 3 pathologists, cases for which there was diagnostic consensus among all 3 reviewers in agreement with the primary contributor (n=60) were used to establish a "consensus group" that served as a gold standard relative to which napsin A performance was assessed. Duplicate, 1.0-mm-core tissue microarrays were constructed from the 54 cases in the consensus group for which requisite materials were available, as well as from 49 endometrial endometrioid carcinomas (all grades) and 17 endometrial serous carcinomas. Napsin A immunohistochemical analysis was performed on the microarrays and on the 17 cases for which there was no diagnostic consensus, with scoring based on the proportion of immunoreactive cells (0, 1+, 2+, and 3+ indicative of 0, 1% to 25%, 26% to 49%, and ≥50% immunoreactive cells, respectively). The distribution of scores for the 49 CCC cases with evaluable cores was as follows: 0, n=6; 1+, n=6; 2+, n=8; 3+, n=29. Among the evaluable cases, the frequency of ≥1+ napsin A immunoreactivity was significantly higher in CCCs (43/49, 88%) than in endometrial serous carcinomas (1/13, 7.7%; P<0.0001) and endometrial endometrioid carcinomas (0/49, 0%; P<0.0001). The sensitivity, specificity, negative predictive value, and positive predictive value of ≥1+ napsin A expression in predicting the consensus clear cell histotype were 0.88 (95% confidence interval [CI], 0.75-0.95), 0.98 (95% CI, 0.9-1), 0.91 (95% CI, 0.86-0.96), and 0.98 (95% CI, 0.86-1), respectively. Napsin A expression was not associated with survival or clinicopathologic factors. In the group of cases without diagnostic consensus for CCC, 50% showed ≥1+ napsin A expression; all napsin A-negative cases had previously been classified as non-CCC by ≥2 reviewers, whereas only 37.5% of the napsin A-positive cases had been classified as CCC by 2 of the 3 reviewers. In conclusion, napsin A is a sensitive and specific biomarker of the clear cell histotype in endometrial carcinomas and accordingly may have diagnostic utility in their histotyping.

AB - The histotyping of high-grade endometrial carcinomas with clear cells may be subject to significant interobserver variability, which suggests that a biomarker that can distinguish endometrial clear cell carcinoma (CCC) from its mimics would be of diagnostic utility. This study assessed the usefulness of napsin A immunohistochemistry in the diagnosis of CCC, on the basis of an analysis of 77 cases diagnosed as such at 9 institutions. After being independently reviewed by a subset of 3 pathologists, cases for which there was diagnostic consensus among all 3 reviewers in agreement with the primary contributor (n=60) were used to establish a "consensus group" that served as a gold standard relative to which napsin A performance was assessed. Duplicate, 1.0-mm-core tissue microarrays were constructed from the 54 cases in the consensus group for which requisite materials were available, as well as from 49 endometrial endometrioid carcinomas (all grades) and 17 endometrial serous carcinomas. Napsin A immunohistochemical analysis was performed on the microarrays and on the 17 cases for which there was no diagnostic consensus, with scoring based on the proportion of immunoreactive cells (0, 1+, 2+, and 3+ indicative of 0, 1% to 25%, 26% to 49%, and ≥50% immunoreactive cells, respectively). The distribution of scores for the 49 CCC cases with evaluable cores was as follows: 0, n=6; 1+, n=6; 2+, n=8; 3+, n=29. Among the evaluable cases, the frequency of ≥1+ napsin A immunoreactivity was significantly higher in CCCs (43/49, 88%) than in endometrial serous carcinomas (1/13, 7.7%; P<0.0001) and endometrial endometrioid carcinomas (0/49, 0%; P<0.0001). The sensitivity, specificity, negative predictive value, and positive predictive value of ≥1+ napsin A expression in predicting the consensus clear cell histotype were 0.88 (95% confidence interval [CI], 0.75-0.95), 0.98 (95% CI, 0.9-1), 0.91 (95% CI, 0.86-0.96), and 0.98 (95% CI, 0.86-1), respectively. Napsin A expression was not associated with survival or clinicopathologic factors. In the group of cases without diagnostic consensus for CCC, 50% showed ≥1+ napsin A expression; all napsin A-negative cases had previously been classified as non-CCC by ≥2 reviewers, whereas only 37.5% of the napsin A-positive cases had been classified as CCC by 2 of the 3 reviewers. In conclusion, napsin A is a sensitive and specific biomarker of the clear cell histotype in endometrial carcinomas and accordingly may have diagnostic utility in their histotyping.

KW - endometrial clear cell carcinoma

KW - immunohistochemistry

KW - napsin A

UR - http://www.scopus.com/inward/record.url?scp=84892958574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892958574&partnerID=8YFLogxK

U2 - 10.1097/PAS.0000000000000085

DO - 10.1097/PAS.0000000000000085

M3 - Article

VL - 38

SP - 189

EP - 196

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 2

ER -